The division entails the diagnosis, treatment, prevention and research in genetic and genomic medicine with respect to precision medicine. It plays an important role in determining the risks of developing certain genetic diseases as well as screening and preventive treatment.
The service is a joint program provided in partnership with Hamad Medical Corporation (HMC). Patients under the age of 18 years, are seen at Sidra Medicine while those the rest at seen at HMC.
Ground-breaking Gene Therapy Programs
We are proud to offer our ground-breaking gene therapy programs for children from across the Middle East and North Africa region.
Duchenne Muscular Dystrophy (DMD) Program: Sidra Medicine is one of the few hospitals in the Middle East to administer Elevidys, a groundbreaking gene therapy developed by Roche Pharmaceuticals. It is currently the only treatment of its kind for DMD.
We were also one of the first hospitals outside of the United States of America, to offer the therapy to children aged eight to eleven years old. By extending this lifesaving therapy beyond traditional age limitations, which were previously restricted to children under the age of six, Sidra Medicine is transforming the lives of DMD patients in the Arab region.
Spinal Muscular Atrophy (SMA) Program: Sidra Medicine has been appointed as the lead treatment center in the MENA region, to administer Zolgensma, a lifesaving drug made by Novartis, for children with SMA.
Since establishing our comprehensive SMA program in 2022, we have had the opportunity to care for over 50 babies with the rare genetic disease.